CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Blue chip cryptos offer resilience, liquidity, and potential for steady growth. Learn the main reasons to consider them as a foundational holding.
19,600 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Tech giants are investing heavily in AI, yet leaders warn that compute costs may outstrip wages. New MIT findings and...
A new milestone for obesity treatment arrives as Novo Nordisk's Wegovy Pill hits 3 million prescriptions. This articl...
NuScale Power has captured headlines with a dramatic stock move. This guide breaks down why nuscale power stock plung...
Verizon fell today after a day of headline-driven moves, including strategic spin-offs and competitive shifts in the ...
Nike has fallen 32% from its pandemic peak, boosting its dividend yield. This article weighs the dividend health, gro...
Meta Platforms dominates online ads with a vast social network and deep data insights. This guide explains why it rem...
ARKK and ARKG are back in the biotech spotlight as Cathie Wood makes new bets after a setback in a key antisense stoc...
As markets swing into February 2026, a core group of performing cash stocks on Cash App are leading gains. This repor...
Is Nebius the nebius next amazon? This article digs into Nebius's model, how it stacks up to Amazon, and what it woul...
A fresh industry study finds that a large share of firms cannot locate all their data as AI tools become part of dail...
Micron stock soaring today is more than a quick move. This guide explains the drivers, how to read the memory market ...